Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
27 oct. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of...
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
26 oct. 2021 16h02 HE
|
Nurix Therapeutics, Inc.
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE...
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
21 oct. 2021 07h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s...
Arvinas to Participate in Upcoming Virtual Investor Conferences
01 sept. 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
05 août 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
13 juil. 2021 16h01 HE
|
Nurix Therapeutics, Inc.
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in...
Global Targeted Protein Degradation Market (2021 to 2030) - by Type of Protein Degrader, Therapeutic Areas, Route of Administration, Key Contributing Technologies and Key Geographies
13 juil. 2021 05h18 HE
|
Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route...
Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
07 juin 2021 17h19 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 07, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
03 juin 2021 07h00 HE
|
Arvinas Inc.
NEW HAVEN, Conn., June 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
02 juin 2021 07h00 HE
|
Nurix Therapeutics, Inc.
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...